REG - Creo Medical Group - First upper GI Speedboat procedure in Europe

Creo MedicalAnnouncement

26/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230626:nRSZ8157Da&default-theme=true

RNS Number : 8157D  Creo Medical Group PLC  26 June 2023

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

First upper GI Speedboat procedure in Europe completed days after clearance

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of surgical endoscopy, announces that Dr Adolfo Parra-Blanco,
from Nottingham University Hospital NHS Trust has become the first clinician
to perform an upper Gastrointestinal ("GI") tract Speedboat Inject case in
Europe since clearance was gained last week.

The procedure saw a 7cm x 5cm cancerous lesion in the stomach removed en-bloc
(in one piece) in a little under two hours and was performed after Dr
Parra-Blanco led an Upper GI Endoscopy Education and Training Day at the
University of Nottingham, where he was able to familiarise himself with the
Speedboat Inject device for use in the upper GI tract.

The result of the procedure was excellent, with the patient leaving hospital
shortly after.

A second doctor is now also trained to use Speedboat Inject for Upper GI
procedures at Nottingham, and Nottingham University Hospital NHS Trust led
Upper GI ESD courses showcasing Speedboat are set to take place next week
(June 28-30) and in August at Queens Medical Centre, Nottingham. Creo will
continue to work closely with Nottingham University Hospital NHS Trust to
support the training, mentoring and adoption of the device by numerous upper
GI specialists over the coming months. This will be in conjunction with Creo's
Pioneer training programme, with the Company expecting a rapid adoption of the
device for upper GI procedures over the coming months.

Dr Parra-Blanco said: "To have this technology now open to us for use in the
upper GI in Europe is fantastic. What's clear to me is how well suited the
Speedboat Inject device is for these types of procedures, and I foresee it
dramatically increasing the number of patients able to benefit from this
advanced energy, not only here in Nottingham but at healthcare settings
elsewhere across Europe."

Craig Gulliford, Chief Executive Officer of Creo Medical said: "To have the
first case completed at such a well-respected and prestigious endoscopic
centre, renowned for its upper GI services, so soon after clearance
demonstrates both the appetite for the device to be used in the upper GI tract
in Europe and the ability for clinicians to quickly get optimal results once
they are familiar with the advanced energy. We look forward to continuing to
work with Nottingham University Hospital NHS Trust and others to maximise the
roll out of the device in the entire GI tract."

 

Enquiries:

 

 Creo Medical Group plc                            www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                +44 (0)1291 606 005

 Cenkos Securities plc                             +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Joint Broker)

 Numis Securities Limited (Joint Broker)           +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                                   Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 / Phillip Marriage

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions.  CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCNKPBDBBKBAAB